论文部分内容阅读
[目的]观察进展期胃癌根治术后序贯放化疗的疗效及不良反应。[方法]收集2008年7月～2010年7月进展期胃癌根治术后患者36例,随机分为序贯放化疗组(16例)和单纯化疗组(20例)。分析比较两组的1年生存率及1年无疾病进展生存率,同时评价治疗期间出现的血液学、胃肠道及肝肾功能等不良反应。[结果]序贯放化疗组和单纯化疗组1年生存率分别为87.5%和65.0%,两组比较差异无统计学意义(P=0.099);1年无疾病进展生存率分别为75.0%和30.0%,差异有统计学意义(P=0.003)。主要不良反应有骨髓抑制、恶心、呕吐、脱发、纳差、腹泻及肝功能损害等,多以Ⅰ～Ⅱ度为主,Ⅲ～Ⅳ度发生率低,均可耐受。两组比较差异均无统计学意义(P>0.05)。[结论]进展期胃癌术后调强放疗序贯5-Fu微泵联合吡柔比星和奥沙利铂化疗与单纯化疗相比,能提高术后1年无疾病进展生存率,急性不良反应轻,可耐受。
[Objective] To observe the curative effect and adverse reactions of sequential chemoradiotherapy after radical gastrectomy for advanced gastric cancer. [Methods] Thirty-six patients with advanced gastric cancer undergoing radical operation from July 2008 to July 2010 were randomly divided into sequential chemoradiotherapy group (n = 16) and chemotherapy alone group (n = 20). The 1-year survival rate and 1-year progression-free survival rate of the two groups were compared. The adverse reactions such as hematology, gastrointestinal tract, liver and kidney function during the treatment were also evaluated. [Results] The 1-year survival rates of sequential radiochemotherapy and chemotherapy alone were 87.5% and 65.0% respectively, with no significant difference between the two groups (P = 0.099). The 1-year disease-free survival rates were 75.0% and 30.0%, the difference was statistically significant (P = 0.003). The main adverse reactions were myelosuppression, nausea, vomiting, alopecia, anorexia, diarrhea and liver dysfunction, mostly in grade Ⅰ ~ Ⅱ, Ⅲ ~ Ⅳ degree of low incidence, are tolerable. There was no significant difference between the two groups (P> 0.05). [Conclusions] Compared with chemotherapy alone, sequential 5-Fu micropump combined with pirarubicin and oxaliplatin chemotherapy can improve the 1-year disease-free survival rate and acute adverse reaction Light, tolerable.